Kailera Therapeutics reported that its oral GLP-1 candidate met primary endpoints in two Chinese Phase 3 obesity and diabetes trials, positioning the asset for regulatory filings in China via its partner Hengrui Pharma. The update indicates 11% weight loss in the program’s reported results, with the trials designed around obesity and diabetes outcomes. Because GLP-1 receptor agonists sit at the center of current metabolic drug demand, a credible oral option with Phase 3 success can shift competitive dynamics in China’s obesity and diabetes market—particularly if it supports convenient dosing compared with injectables. The next phase is expected to move through Hengrui’s path toward approval in China, contingent on the full dataset and regulatory review process.